Schwab Charles Investment Management Inc. Acquires 4,335 Shares of AnaptysBio Inc (ANAB)

Schwab Charles Investment Management Inc. grew its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 5.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 79,275 shares of the biotechnology company’s stock after buying an additional 4,335 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.33% of AnaptysBio worth $8,251,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. State of Wisconsin Investment Board lifted its holdings in shares of AnaptysBio by 52.9% in the 1st quarter. State of Wisconsin Investment Board now owns 18,200 shares of the biotechnology company’s stock worth $1,894,000 after acquiring an additional 6,300 shares during the last quarter. Swiss National Bank lifted its holdings in shares of AnaptysBio by 5.7% in the 1st quarter. Swiss National Bank now owns 20,500 shares of the biotechnology company’s stock worth $2,134,000 after acquiring an additional 1,100 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of AnaptysBio by 49.0% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,733 shares of the biotechnology company’s stock worth $909,000 after acquiring an additional 2,870 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of AnaptysBio by 11.5% in the 1st quarter. American Century Companies Inc. now owns 22,552 shares of the biotechnology company’s stock worth $2,347,000 after acquiring an additional 2,322 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of AnaptysBio in the 1st quarter worth about $495,000.

Shares of ANAB opened at $75.25 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.57 and a quick ratio of 17.57. The stock has a market cap of $1.77 billion, a P/E ratio of -49.51 and a beta of 2.98. AnaptysBio Inc has a 1-year low of $20.12 and a 1-year high of $134.00.



AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.19). During the same period in the prior year, the firm earned ($0.75) EPS. research analysts forecast that AnaptysBio Inc will post -3.04 EPS for the current fiscal year.

Several equities research analysts have recently issued reports on ANAB shares. ValuEngine upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Jefferies Financial Group raised their target price on shares of AnaptysBio from $6.59 to $145.00 and gave the stock a “buy” rating in a report on Monday, February 19th. JMP Securities set a $180.00 target price on shares of AnaptysBio and gave the stock a “buy” rating in a report on Tuesday, March 27th. Stifel Nicolaus set a $152.00 target price on shares of AnaptysBio and gave the stock a “buy” rating in a report on Monday, March 26th. Finally, Royal Bank of Canada raised their target price on shares of AnaptysBio to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $131.44.

In other AnaptysBio news, Director Nicholas Lydon sold 33,000 shares of the stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $86.88, for a total transaction of $2,867,040.00. Following the completion of the transaction, the director now owns 301,506 shares of the company’s stock, valued at $26,194,841.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 20.80% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply